Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Sheds Select Product Assets In Mid-East, Emerging Markets To Acino

Executive Summary

In a continued effort to pay down its debt pile from the acquisition of Shire, Takeda is to offload around 30 selected OTC and Rx products in certain Middle East and other emerging markets to private Swiss group Acino.

You may also be interested in...



Takeda Offloads Surgical Patch To Corza Health For €350M

Johnson & Johnson previously agreed to acquire TachoSil but terminated the transaction due to regulatory hurdles.

Hypera Pays $825m For Takeda LatAm Portfolio

Major new portfolio divestment, along with Deerfield site sale, form part of ongoing effort to pay down Shire-related debt and focus on novel drugs.

Takeda Sheds Products, Employees To Stada In $660m Move

Takeda offloads more assets as it focuses on core therapeutic areas and innovative drugs, this time a portfolio of products in emerging markets, with around 500 employees also affected.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC126021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel